Novel Antimicrobials and AMR Diagnostics 2019

Programme - Day 1

Overview of preliminary programme structure

At a glance | Day 1 | Day 2


Pre-conference Workshop
"Resistance testing – beyond serial passage experiments"
Jointly organised by Novo Repair Impact Fund, CARB-X, GARDP and Wellcome Trust

Emergence of mutational resistance - Threat or myth?
Ursula Theuretzbacher, Center for Anti-Infective Agents, AT

Testing of dual/multiple target drugs
Michael Mourez, Evotec ID Lyon, FR 

Testing of single target drugs
Diarmaid Hughes, Uppsala University & ENABLE, SE

// open to all conference delegates – limited seats available; register via the online form  //


Pre-conference Meeting
BEAM Alliance General Assembly
// for members only //


15:00–19:00 Registration, Poster Presentations and Exhibition open
16:00–17:45Plenary Session

Policy Session – Part I 
How to leverage public and private support to efficiently finance AMR innovation?
Co-organised with WHO and UNCTAD

The Policy Session will be organised together with WHO/UNCTAD and will serve as a follow-up of the AMR session at the World Investment Forum in October 2018. After introductory presentations a panel debate will discuss major challenges of setting up a new AMR investment fund.

• Christoph Spennemann, UNCTAD (Moderator)
• Marc Gitzinger, Bioversys AG & BEAM Alliance Board Member, CH
• Peter Beyer, WHO
• Kevin Outterson, CARB-X, US
• Christian Riemann, Global Investment Bridge AG & Bacteriobator Accelerator, DE
• Anand AnandKumar, Bugworks, IN
• Ruby Holder, Roivant Sciences, US

17:45–18:00 Break
18:00–19:30Parallel Sessions and Investor Partnering

Policy Session – Part II
Workshop: How to set up a new AMR innovation fund?
Co-organised with WHO and UNCTAD

Round table discussions in smaller groups will analyse main parameters for setting up a new AMR innovation fund 

Session 1
Academic Innovations
The session will highlight application-oriented academic research on AMR therapeutics and diagnostics. It will be opened by an introduction that emphasizes the role of academia in product development.

• Till Bachmann, University of Edinburgh, UK 
• Olga Genilloud, Foundation Medina, ES
• Jean-Claude Sirard, INSERM, FR
• Robin Michelet, FU Berlin, DE
• Martin Caffrey, Trinity College Dublin, IE
• Richard Grohs, Leibniz Institute of Photonic Technology, InfectoGnostics Research Campus, Jena, DE

Session 2
Non-traditional Approaches and Enabling Technologies
The session will showcase therapeutic developments that go beyond traditional small molecule approaches as well as platform technologies that enables the discovery and development of new antibiotics, alternatives to antimicrobials, AMR therapies and diagnostic approaches.

• Ute Kilger, Boehmert & Boehmert, DE (Moderation)
• Magnus Jansson, Symcel, SE
• Egill Másson, Akthelia, IS
• Dave Ousterout, Locus Biosciences, US
• Achim Plum, Ares Genetics, AT
• Jennifer Schneider, Centauri Therapeutics, UK
• Claus Stie Kallesøe, Grit42, DK
• Susana Tomasio, CDD Vault, UK

Investor Partnering
Pre-scheduled 1-to-1 meetings (18:00–20:00)
19:30–21:30 Welcome Reception
Location: Radisson Blu Hotel – Foyer Berliner Dom, 7th Floor 
// open to all conference attendees – please note: additional fee applies //